Jacobs Levy Equity Management
DARE icon

Jacobs Levy Equity Management’s Dare Bioscience DARE Stock Holding History

Jacobs Levy Equity Management’s Portfolio DARE Stock Details DARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,965
Closed -$247K – 983
2016
Q3 		$247K Buy
1,965
+1,228
+167% +$275K ﹤0.01% 850
2016
Q2 		$187K Buy
+737
New +$236K ﹤0.01% 1018

Other funds holding DARE

PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
DVC
Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Jacobs Levy Equity Management's DARE Position: Q4 2016 in Review

Jacobs Levy Equity Management sold out of Dare Bioscience (DARE) in Q4 2016, closing a stake of 1,965 shares — an estimated $247K sold.

Jacobs Levy Equity Management first reported a position in DARE in Q2 2016 and held it in 2 quarters. The position peaked at $247K in Q3 2016. 30 funds tracked by Wall St. Rank hold DARE as of Q4 2016.

  • Jacobs Levy Equity Management reported no remaining Dare Bioscience position as of Q4 2016 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 1,965 Dare Bioscience shares in Q4 2016, an estimated $247K.
  • Jacobs Levy Equity Management first reported a position in Dare Bioscience in Q2 2016 and held it in 2 quarters.
  • Jacobs Levy Equity Management's Dare Bioscience position peaked at $247K in Q3 2016.
  • 30 funds tracked by Wall St. Rank held Dare Bioscience as of Q4 2016.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2016, filed 14 Feb 2017.